MASIMO CORP: management transactions · United States · SEC (Form 4)

About MASIMO CORP

Masimo Corp. (ticker: MASI) is a U.S.-based medical technology company listed on the NASDAQ in the United States and headquartered in Irvine, California. Founded in 1989 by Joe Kiani as a private garage start-up, Masimo has evolved into a global leader in noninvasive patient monitoring, with more than 7,000 employees worldwide. The company’s core franchise centers on physiological monitoring technologies, especially pulse oximetry, but its portfolio has expanded well beyond that initial breakthrough into a broader platform for hospital automation, connectivity, and telehealth. ([masimo.com](https://www.masimo.com/company/masimo/about/?utm_source=openai)) Masimo’s competitive position is built on clinically validated innovation and strong penetration in high-acuity care settings. The company highlights its SET® technology as the first “measure-through motion and low perfusion” pulse oximetry, designed to deliver reliable readings in difficult clinical conditions. That performance positioning has been a key differentiator in the company’s brand and commercial strategy, helping support adoption by leading hospitals and by OEM partners that embed Masimo technology in third-party monitoring devices. ([masimo.com](https://www.masimo.com/company/about/?utm_source=openai)) From a product perspective, Masimo offers sensors, patient monitors, connectivity modules, automation solutions, and advanced monitoring tools such as rainbow® pulse CO-oximetry, SedLine® brain function monitoring, O3® regional oximetry, and capnography. The Root® platform is an important part of the company’s ecosystem because it is designed to combine multiple Masimo and third-party monitoring capabilities in a modular architecture. This broader platform approach allows Masimo to serve operating rooms, ICUs, emergency care, and selected home-care or remote-monitoring use cases. ([masimo.com](https://www.masimo.com/products/sensors/brain-monitoring/sedline/?utm_source=openai)) Geographically, Masimo retains a strong U.S. operational base in Irvine while selling globally. The company presents itself as a worldwide medical technology provider whose solutions are intended to improve outcomes, streamline workflows, and extend noninvasive monitoring into new sites of care. Its international reach is supported both by direct commercialization and by licensing relationships with major medtech manufacturers. ([masimo.com](https://www.masimo.com/company/masimo/about/?utm_source=openai)) Recent developments are especially material for investors. In 2025, Masimo reported quarterly results and continued to advance new clinical evidence and FDA-cleared product enhancements, including updates for O3® regional oximetry. The most significant headline in 2026 is Masimo’s announced agreement to be acquired by Danaher for $180.00 per share in cash, implying total consideration of $9.9 billion, subject to customary closing conditions. For equity investors following SEC Form 4 insider activity, that transaction context is important because it frames the stock around event-driven M&A dynamics rather than purely standalone operating performance. ([masimo.com](https://www.masimo.com/media/masimo-to-be-acquired-by-danaher?utm_source=openai))